source
- IQVIA report finds 90% of drugs launched 2016-2020 unlikely to recoup costsIQVIA analyzed 825 novel medicines launched in the United States between 1991 and 2020 and found that profitability has sharply declined over time. For drugs launched from 2016 to 2020, a positive…
- Novo’s CagriSema shows over 20% weight loss at low doses in Phase 3 trialNovo Nordisk presented new Phase 3 data on its experimental obesity combo CagriSema at ObesityWeek 2026. The low‑dose arm (1 mg and 1.7 mg weekly) achieved average weight reductions of about 21% a…